(Q42802864)

7 November 2017

title

A method to increase the number of growth hormone receptors at the surface of cells (English)

1 reference

7 November 2017

1 reference

https://api.crossref.org/works/10.1016/S0303-7207(02)00434-3

26 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0303-7207(02)00434-3

26 December 2023

author name string

Peter van Kerkhof

1

1 reference

7 November 2017

Erica Vallon

2

1 reference

7 November 2017

Ger J. Strous

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706294

26 December 2023

language of work or name

1 reference

1 March 2003

1 reference

7 November 2017

28 March 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12706294

full work available at URL

26 December 2023

https://api.elsevier.com/content/article/PII:S0303720702004343?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0303-7207(02)00434-3

https://api.elsevier.com/content/article/PII:S0303720702004343?httpAccept=text/plain

26 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0303-7207(02)00434-3

Molecular and Cellular Endocrinology

26 December 2023

published in

1 reference

7 November 2017

volume

201

1 reference

7 November 2017

issue

1-2

1 reference

7 November 2017

page(s)

57-62

1 reference

Development of the proteasome inhibitor PS-341.

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Blockade of growth hormone receptor shedding by a metalloprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Growth hormone binding protein 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Ubiquitin-mediated degradation of cellular proteins in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

The proteasome: a new target for novel drug therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Processing of tumour necrosis factor-α precursor by metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Phorbol ester- and growth factor-induced growth hormone (GH) receptor proteolysis and GH-binding protein shedding: relationship to GH receptor down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Basic Medical Research Award. The ubiquitin system

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Metalloproteinase-mediated release of human Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Robert H Herman Memorial Award in Clinical Nutrition Lecture, 1997. Mechanisms causing loss of lean body mass in kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Transcription factors and muscle cachexia: is there a therapeutic target?

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Jak2 and proteasome activities control the availability of cell surface growth hormone receptors during ligand exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

The ubiquitin-proteasome pathway and the regulation of growth hormone receptor availability

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Proteasome inhibitor enhances growth hormone-binding protein release

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Endocytosis and degradation of the growth hormone receptor are proteasome-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

The ubiquitin-proteasome pathway regulates the availability of the GH receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900434-3

7 January 2021

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma

29

1 reference

https://api.crossref.org/works/10.1016/S0303-7207(02)00434-3

26 December 2023

Identifiers

1 reference

7 November 2017

1 reference